Amanda Juliana Sales

Amanda Juliana Sales

Auto-generated profile, based on publicly available information

Amanda Juliana Sales

Department of Pharmacology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirao Preto, SP, Brazil

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
ASAmanda J. Sales
Amanda J. Sales
MFManoela V. Fogaça
Manoela V. Fogaça
ASAriandra G. Sartim
Ariandra G. Sartim
VPVitor S. Pereira
Vitor S. Pereira
GWGregers Wegener
Gregers Wegener
SJSamia Joca
Samia Joca

23 May 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
Alline CamposAlline Campos
Alline Campos
MFManoela V. Fogaça
Manoela V. Fogaça
FSFranciele F. Scarante
Franciele F. Scarante
SJSamia Joca
Samia Joca
ASAmanda J. Sales
Amanda J. Sales
FGFrancisco S. Guimarães
Francisco S. Guimarães
Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces plastic changes. For example, CBD attenuates the decrease in hippocampal neurogenesis and dendrite spines density induced by chronic stress and prevents microglia activation and the decrease in the number of parvalbumin-positive GABA neurons in a pharmacological model of schizophrenia. More recently, it was found that CBD modulates cell fate regulatory pathways such as autophagy and others critical pathways for neuronal survival in neurodegenerative experimental models, suggesting the potential benefit of CBD treatment for psychiatric/cognitive symptoms associated with neurodegeneration. These changes and their possible association with CBD beneficial effects in psychiatric disorders are reviewed here.

17 May 2011 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
ASAmanda J Sales
Amanda J Sales
CBCaroline Biojone
Caroline Biojone
MTMateus S Terceti
Mateus S Terceti
FGFrancisco S Guimarães
Francisco S Guimarães
MGMarcus Vm Gomes
Marcus Vm Gomes
SJSamia Joca
Samia Joca
BACKGROUND AND PURPOSE Epigenetic modifications are thought to play an important role in the neurobiology of depression. Antidepressant treatment induces histone acetylation in the hippocampus, which is associated with transcriptional activation, whereas stress increases DNA methylation, which is associated with transcriptional repression. Because the specific involvement of DNA methylation in the regulation of depressive‐like behaviours is not yet known, we have investigated the effects induced by systemic or intra‐hippocampal administration of inhibitors of DNA methyltransferase (DNMT) in rats submitted to a range of behavioural tests.EXPERIMENTAL APPROACH Rats received i.p. injections of 5‐aza‐2‐deoxycytidine (5‐azaD, 0.1–0.8 mg·kg−1), 5‐azacytidine (5‐azaC, 0.4–3.2 mg·kg−1), imipramine (15 mg·kg−1) or vehicle and were submitted to the forced swimming test (FST) or open field test (OFT). Other groups of rats received intra‐hippocampal injection of DNMT inhibitors.KEY RESULTS Systemic administration of DNMT inhibitors induced a dose‐dependent antidepressant‐like effect, which was followed by decreased DNA methylation and increased brain‐derived neurotrophic factor (BDNF) levels in the hippocampus. Hippocampal inhibition of DNA methylation induced similar behavioural effects. No treatment induced any locomotor effects in the OFT. Antidepressant‐like effects of 5‐azaD were confirmed in mice submitted to the FST or the tail suspension test.CONCLUSIONS AND IMPLICATIONS Systemic, as well as hippocampal, inhibition of DNA methylation induced antidepressant‐like effects. These effects could be associated with increased hippocampal expression of BDNF. Our data give further support to the hypothesis that DNA methylation is an important epigenetic mechanism involved in the development of depressive‐like behaviours.

1 August 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
ASAmanda J. Sales
Amanda J. Sales
CCCarlos C. Crestani
Carlos C. Crestani
FGFrancisco S. Guimarães
Francisco S. Guimarães
SJSamia Joca
Samia Joca

1 July 2019 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
GSGabriela Pandini Silote
Gabriela Pandini Silote
ASAriandra Sartim
Ariandra Sartim
ASAmanda Sales
Amanda Sales
AEAmanda Eskelund
Amanda Eskelund
FGF.S. Guimarães
F.S. Guimarães
SJSamia Joca
Samia Joca

1 August 2001 in Brain Research Bulletin
Verified
Journal Article
Closed access
CLCilene Lino-De-Oliveira
Cilene Lino-De-Oliveira
ASAmanda J Sales
Amanda J Sales
EDElaine Del-Bel
Elaine Del-Bel
MSMaria Cristina Leite Silveira
Maria Cristina Leite Silveira
FGFrancisco Silveira Guimarães
Francisco Silveira Guimarães